EGFR and glioblastoma: Although EGFR inhibitors have failed Phase II clinical trials in GBM therapy [57,58], these molecules can be reconsidered in combination therapy with antipsychotics due to their effect on the MAPK pathway by the antagonism of EGFR and DR isoform D2, respectively [59].